Edinburgh Medical School, University of Edinburgh, UK.
Academic Unit for Ageing and Stroke Research, University of Leeds, UK.
Age Ageing. 2021 May 5;50(3):996-1000. doi: 10.1093/ageing/afaa198.
At all ages, randomised trials demonstrate lower mortality and cardiovascular disease incidence with blood pressure (BP) lowering. However, this may not generalise to older people with frailty. We aimed to determine the acceptability to clinicians of key aspects of trial designs using different BP targets and strategies to better manage hypertension in the context of frailty.
We conducted a multinational survey of clinicians managing hypertension in older people, distributed using an online survey link amongst professional societies and social networks. Questions described case histories of patients who were frail with different systolic blood pressures (SBP), treatment target, strategy and target trial population.
In total, 114 responses were received (48 primary care, 66 secondary care). A majority would consider recruiting patients to a trial of relaxing treatment in those whose SBP < 130 mm Hg; a majority would consider recruiting to a trial intensifying treatment in patients with SBP > 150 mm Hg. Respondents elected to intensify treatment by: choosing the next step by NICE guidelines, adding a new treatment agent at full dose, or adding two agents at half dose.
A majority of clinicians surveyed would recruit older people to a trial intensifying treatment where SBP is more than 150 mm Hg and where patients have high cardiovascular risk or to a trial relaxing treatment where the SBP is below 130 mm Hg and where the patient has frailty.
在所有年龄段,随机试验都表明降低血压(BP)可降低死亡率和心血管疾病发病率。然而,这可能不适用于患有衰弱症的老年人。我们旨在确定使用不同的 BP 目标和策略来更好地管理衰弱症背景下的高血压的临床试验设计的关键方面对临床医生的可接受性。
我们对管理老年人高血压的临床医生进行了一项多国家调查,使用在线调查链接在专业协会和社交网络中进行了分发。问题描述了不同收缩压(SBP)、治疗目标、策略和目标试验人群的虚弱患者的病史。
共收到 114 份回复(48 份来自初级保健,66 份来自二级保健)。大多数人会考虑招募收缩压 < 130 mmHg 的患者参加放松治疗试验;大多数人会考虑招募收缩压 > 150 mmHg 的患者参加强化治疗试验。受访者通过以下方式选择强化治疗:根据 NICE 指南选择下一步,全剂量添加新的治疗药物,或半剂量添加两种药物。
大多数接受调查的临床医生会招募收缩压超过 150 mmHg 且心血管风险高的老年人参加强化治疗试验,或者招募收缩压低于 130 mmHg 且患有衰弱症的患者参加放松治疗试验。